Ornithine
L-Ornithine
An amino acid involved in the urea cycle that may reduce fatigue and support recovery, especially during prolonged exercise.
L-Ornithine is a non-protein amino acid that plays a central role in the urea cycle, helping the body eliminate ammonia. During intense or prolonged exercise, ammonia accumulates and contributes to fatigue. Ornithine supplementation may help clear ammonia more efficiently, reducing fatigue and supporting recovery. It's often combined with arginine for synergistic effects on growth hormone and exercise performance.
Mechanisms of Action
Urea Cycle Enhancement
Accelerates ammonia detoxification
Ammonia Reduction
Helps clear exercise-induced ammonia buildup
Growth Hormone Support
May stimulate GH release when combined with arginine
Recommended Dose
2-6g daily
Loading: Not required
Optimal Timing
- Before exercise for fatigue reduction
- Before bed for sleep support
Take with food
Best Form
L-Ornithine HCl
Alternatives: L-Ornithine capsules, OKG (Ornithine Alpha-Ketoglutarate)
Often sold in combination with arginine. OKG may have enhanced effects.
Duration
Minimum: 2 weeks
Optimal: 8 weeks
Cycling: Not required
Note: Can be combined with arginine. For sleep benefits, take 30-60 minutes before bed.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Reduced Fatigue
Less ammonia-related exhaustion during exercise
Faster Recovery
Improved recovery between training sessions
Improved Sleep Quality
May enhance sleep, especially after stress or exercise
GI Discomfort
May cause digestive upset at high doses
Limited data; consult healthcare provider
May benefit those with high ammonia production
Who Should NOT Take This
- Severe kidney disease
- Urea cycle disorders
Possible Side Effects
Tip: Take with food; reduce dose
Tip: Reduce dose; divide into smaller doses
Warnings
- Most beneficial for prolonged or exhaustive exercise
- Effects may be modest in recreational exercisers
Top studies from 40+ peer-reviewed papers
Langer G et al. • The Cochrane database of systematic reviews (2024)
“The benefits of nutritional interventions with various compositions for pressure ulcer prevention and treatment are uncertain.”
Key Findings:
- Compared to standard diet, protein supplements may result in little to no difference in pressure ulcer incidence (protein 21 per 1000, standard diet 28 per 1000; RR 0.75, 95% CI 0.49 to 1.14; 4 studies, 4264 participants; low-certainty evidence).
- The evidence is very uncertain about the gastrointestinal side effects of these supplements (protein 109 per 1000, standard diet 155 per 1000; RR 0.70, 95% CI 0.06 to 7.96; 2 studies, 140 participants, very low-certainty evidence).
- Compared to standard diet, energy, protein and micronutrient supplements may slightly increase the number of healed pressure ulcers (energy, protein and micronutrients 366 per 1000, standard diet 253 per 1000; RR 1.45, 95% CI 1.14 to 1.85; 3 studies, 577 participants, low-certainty evidence).
- Compared to standard diet, supplements with arginine and micronutrients may not increase the number of healed pressure ulcers, but the evidence suggests a slight reduction in pressure ulcer area (MD 15.8% lower, 95% CI 25.11 lower to 6.48 lower; 2 studies, 231 participants, low-certainty evidence).
Ramanathan G et al. • Metabolomics : Official journal of the Metabolomic Society (2025)
“These identified metabolites hold potential as early markers for T2D-induced DKD.”
Key Findings:
- These identified metabolites hold potential as early markers for T2D-induced DKD.
- However, the use of these metabolites for clinical purposes requires experimental validation and clinical trials.
- Further research warranted to confirm findings
Zinellu A et al. • Cells (2023)
“Our study suggests that the presence of significant alterations in metabolites within the arginine, transsulfuration, and folic acid pathways can be useful for assessing nitric oxide dysregulation and oxidative stress and identifying novel treatment targets in COPD. (PROSPERO registration number: CRD42023448036.).”
Key Findings:
- Additionally, COPD was associated with significantly higher ADMA (SMD = 1.27, 95% CI 0.08 to 2.46, p = 0.037), SDMA (SMD = 3.94, 95% CI 0.79 to 7.08, p = 0.014), and ornithine concentrations (SMD = 0.67, 95% CI 0.13 to 1.22, p = 0.015).
- In subgroup analysis, the SMD of homocysteine was significantly associated with the biological matrix assessed and the forced expiratory volume in the first second to forced vital capacity ratio, but not with age, study location, or analytical method used.
- Further research warranted to confirm findings
Pulik K et al. • Cells (2023)
“Metabolomics, by searching for biomarkers and distinguishing metabolic pathways, can allow us to understand the pathophysiology of COPD and the development of its phenotypes.”
Key Findings:
- However, about 75% of smokers do not develop the disease despite the severe smoking burden.
- Sphingolipids, phosphatidylethanolamines, and sphingomyelins distinguished COPD from non-smokers; volatile organic compounds, lipids, and amino acids distinguished COPD from smokers without the disease.
- Five volatile organic compounds were correlated with eosinophilia and four were associated with a phenotype with frequent exacerbations.
- Fatty acids and ornithine metabolism were correlated with the severity of COPD.
Onoja A et al. • International journal of molecular sciences (2023)
“Whilst the studies reviewed here were small and may be subject to confounders, it is desirable that biomarker panels be resilient across cohorts if they are to find use in the clinic, highlighting the importance of assessing the robustness and reproducibility of metabolomics analyses in independent populations.”
Key Findings:
- We further evaluate a crowdsourced panel comprising the COVID-19 metabolomics biomarkers most commonly mentioned in the literature between 2020 and 2023.
- The best-performing panel in the independent dataset-measured by F1 score (0.76) and AUROC (0.77)-included nine biomarkers: lactic acid, glutamate, aspartate, phenylalanine, β-alanine, ornithine, arachidonic acid, choline, and hypoxanthine.
- Panels comprising fewer metabolites performed less well, showing weaker statistical significance in the independent cohort than originally reported in their respective discovery studies.
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.